News & Updates

February 10, 2022

PyrAmes selected for LG NOVA’s Mission for the Future global challenge “First 50”

Global Challenge

mission futurePyrAmes chosen from 1,300+ applicants to collaborate with LG on innovative connected health products. CUPERTINO, CA, February 10, 2022 -- PyrAmes, Inc., a digital healthcare company focused on innovative products for continuous blood pressure monitoring, today announced its selection by the LG Electronics North American Innovation Center, LG NOVA in its inaugural cohort of startups selected in its large-scale Mission for the Future global challenge competition. Chosen from a group of over 1,300 applicants, the “First 50” companies represent new developments in several areas including Connected Health, and will work with the LG NOVA team on their business concepts. (more…)
January 17, 2022

PyrAmes Technology Featured in Neonatal Intensive Care Journal

PyrAmes Technology

The PyrAmes Boppli™ device is featured on page 11 in the Winter 2022 edition of Neonatal Intensive Care: The Journal of Perinatology-Neonatology. The article focuses on how the Boppli is being developed to meet the need for continuous, non-invasive blood pressure monitoring in the neonatal intensive care unit (NICU).
December 1, 2021

PyrAmes selected for Plug and Play Japan’s Winter/Spring 2022 Batch Accelerator Program

Accelerator Program

Plug and Play Japan and its 49 corporate partners have selected PyrAmes for its global accelerator program, including 67 companies from Japan, the U.S., Canada, India, the United Kingdom, Spain, and more. PyrAmes receives business development resources in the program’s Health track, focusing on Plug and Play’s interest in sensors and wearables. Plug and Play Japan is a subsidiary of Plug and Play; a global innovation platform headquartered in Silicon Valley. Its major strength is to provide consortium-type programs with its extensive global network.
June 22, 2021

International Journal Sensors Showcases PyrAmes Technology and Applications

Value of PyrAmes

PyrAmes’ breakthrough blood pressure sensor is featured in Sensors, the leading international, peer-reviewed journal on the science and technology of sensors. The paper, Advances in Non-Invasive Blood Pressure Monitoring, highlights the added value of PyrAmes’ novel algorithm-based blood pressure sensor which uses machine-learning techniques to extract blood pressure values from the shape of the pulse waveform. The paper reports results from preliminary studies on a range of patient populations and discusses the accuracy and limitations of this capacitive-based technology and its potential application in hospitals and communities.
April 20, 2021

PyrAmes Raises $6 Million in Series A Financing

Cupertino, CA, -- (Marketwired - April 20, 2021) – PyrAmes, Inc., a digital healthcare company focused on innovative products for continuous blood pressure monitoring, today announced the completion of a $6 million Series A financing. The investment round was led by GSR Ventures, with co-investments from Keytone Ventures, XTX Ventures and other investors. (more…)
May 18, 2020

FDA Breakthrough Device Designation

Medical Device

PyrAmes Inc. is proud to announce that the FDA has granted Breakthrough Device Designation (BDD) to Boppli™, which fills the unmet need of monitoring the blood pressure of critically ill infants when an invasive arterial catheter cannot be used due to the risk of complications and adverse effects. (more…)
April 15, 2020

SWPDC Pediatric Device Award

Pediatric Device

PyrAmes is honored to be selected by the Southwest National Pediatric Device Innovation Consortium (SWPDC) as a winner of the SWPDC Spring Competition. The SouthWest National Pediatric Device Innovation Consortium (SWPDC) is a “free no-strings-attached” virtual accelerator based at Texas Children’s Hospital and Baylor College of Medicine that supports pediatric device innovators nationwide throughout the pediatric device life cycle. The goal of the SWPDC is to accelerate commercialization and clinical use of novel pediatric devices.
April 1, 2020

PyrAmes Awarded SBIR Phase I Grant from NIH

Product Development

PyrAmes is pleased to announce it has been awarded a Phase I grant from the National Institutes of Health. The Grant will be used for ongoing product development as well as clinical validation studies. A key objective of the NIH Grant Program is to facilitate development of promising medical technologies. The content of this announcement is solely the responsibility of the author and does not necessarily represent the official views of the NIH.
February 18, 2020

Founding Member of CDC National Hypertension Control Roundtable

Record Levels

With hypertension reaching record levels, PyrAmes has joined with the Centers for Disease Control (CDC) in the formation of the National Hypertension Control Roundtable. The Roundtable was formed in 2020 along with 50 other organizations committed to reversing this trend. Nearly half of adults in the US suffer from hypertension, but only about 1 in 4 cases are well-managed. The US Surgeon General has issued a “Call to Action” to make hypertension control a national priority and to optimize patient care for hypertension.
December 16, 2019

PyrAmes Awarded SBIR Phase I Grant from USAF

Air Force

PyrAmes is pleased to announce it has been awarded a Phase I grant from the United States Air Force (USAF) AFWERX program. Pyrames was part of a select group of companies asked to undertake a feasibility study to determine product viability within the Department of Defense (DoD). AFWERX is a program within the USAF and was formed in 2017 as a vehicle to fuel innovation within the private sector. The ultimate goal of the program is to address unmet needs and enhance the effectiveness of the Air Force.